SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on January 26, 2023, covering events occurring on January 25, 2023. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The filing discloses the entry into a material definitive agreement involving the sale of unregistered equity securities.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard periodic financial results. Key metrics from the transaction include:
- Total Consideration Raised: $159,997.87
- Common Shares Sold: 196,872 shares
- Price Per Share: $0.8127
- Warrants Issued: Warrants to purchase up to 98,436 shares (50% of shares sold)
- Warrant Exercise Price: $0.7502 per share
- Warrant Terms: Exercisable six months after issuance; expire five and one-half years after issuance
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, total debt, or liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the increase in outstanding common stock and the creation of potential future dilution through the issuance of warrants. The transaction was conducted under Section 4(a)(2) and Regulation D (Rule 506) exemptions from registration under the Securities Act of 1933.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard representations and warranties typical for such transactions. The company noted that the summaries of the Purchase Agreement and Warrants are qualified by reference to the full text of the exhibits attached to the report.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess immediate dilution.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on the company.
- Confirm the identity of the institutional and accredited investors involved in the purchase.
- Monitor the company's cash position to determine if the $160,000 raised is sufficient for near-term operational needs.
- Check subsequent filings for any changes in the warrant exercise terms or early exercise provisions.